Big Pharma’s Covid-19 Profiteers
How the race to develop treatments and a vaccine will create a historic windfall for the industry — and everyone else will pay the price
Related Articles
A New Look at P Values for Randomized Clinical Trials
We have examined the primary efficacy results of 23,551 randomized clinical trials from the Cochrane Database of Systematic Reviews.We estimate that the great majority of…
Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI
REDUCE-AMI showed no benefit for routine beta-blockers post–MI in patients with normal ejection fraction. John Mandrola, MD, asks: Does evidence-based medicine need expiration dates?
Grilling the data: application of specification curve analysis to red meat and all-cause mortality
To present an application of specification curve analysis—a novel analytic method that involves defining and implementing all plausible and valid analytic approaches for addressing a…
Grilling the data: application of specification curve analysis to red meat and all-cause mortality
To present an application of specification curve analysis—a novel analytic method that involves defining and implementing all plausible and valid analytic approaches for addressing a…
Preventive Coronary Stents: Not There Yet
The PREVENT trial on stenting stable plaques deemed vulnerable by imaging criteria suggests a benefit over medical therapy alone. John Mandrola, MD, finds it provocative…
Grilling the data: application of specification curve analysis to red meat and all-cause mortality
To present an application of specification curve analysis—a novel analytic method that involves defining and implementing all plausible and valid analytic approaches for addressing a…
Preventive Coronary Stents: Not There Yet
The PREVENT trial on stenting stable plaques deemed vulnerable by imaging criteria suggests a benefit over medical therapy alone. John Mandrola, MD, finds it provocative…
We’re Number One—Thanks to You
You’re one of 630,591 Free Pressers. Help us make you one in a million.
Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI
REDUCE-AMI showed no benefit for routine beta-blockers post–MI in patients with normal ejection fraction. John Mandrola, MD, asks: Does evidence-based medicine need expiration dates?